Global Medical REIT Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMRE research report →
Range $11 – $40
Price Chart
About the company
Global Medical REIT Inc. operates as a specialized real estate investment trust (REIT) focused on net-lease medical office properties. The company's core activity involves purchasing and subsequently leasing custom-designed healthcare facilities to well-established healthcare systems and physician practices that command a significant share of their market.
- CEO
- Mark O. Decker Jr.
- IPO
- 2016
- Employees
- 26
- HQ
- Bethesda, MD, US
Get TickerSpark's AI analysis on GMRE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $478.13M
- P/E
- 6.96
- Fwd P/E
- 595.67
- PEG
- -0.00
- P/S
- 2.16
- P/B
- 0.52
- EV/EBITDA
- 6.40
- Div Yield
- 8.95%
- Gross Margin
- -4.51%
- Op Margin
- 19.45%
- Net Margin
- 36.62%
- ROE
- 9.93%
- ROIC
- 3.71%
Latest fiscal year · YoY change
- Revenue
- $148.21M+7.1%
- Gross Profit
- $0-100.0%
- Op Income
- $0
- Net Income
- $-12,116,000-282.7%
- EPS
- $-0.91-393.5%
- OCF Growth
- +5.1%
- FCF Growth
- +393.6%
- 52W High
- $45.75
- 52W Low
- $29.05
- 50D MA
- $35.15
- 200D MA
- $34.06
- Beta
- 1.20
- RSI (14)
- 53
- Avg Volume
- 105.80K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Chiron reported steady third-quarter operating results while advancing its strategy to sell outpatient medical assets and redeploy capital into seniors housing.· November 5, 2026
- NAREIT-defined FFO per share and unit was $0.50; core FFO was $0.75.
- Outpatient Medical same-store cash NOI rose 1.6% year over year, in line with expectations.
- The company ended the quarter with $231 million of unutilized borrowing capacity, 41% leverage under its credit agreement, and 7.1x net debt to adjusted EBITDA.
- Management said it has closed over $430 million of proprietary seniors housing investments this year and remains focused on repositioning the portfolio.
- Lease-up at The Landing remained strong at 95.1% occupancy, while The Riviera and The Pinnacle are still early in their ramp.
- Management said MOB pricing has weakened as treasury rates moved, but the process is ongoing and they are encouraged by interest.
Third-quarter NAREIT-defined FFO per share and unit was $0.50, and core FFO was $0.75 per share and unit. Outpatient Medical same-store cash NOI increased 1.6% year over year. Cash G&A was $5.3 million, including $1.2 million of severance and transition costs; excluding those items, cash G&A would have been $4.1 million. The company ended the quarter with $231 million of unutilized borrowing capacity, a 41% leverage ratio under its credit agreement, and net debt to adjusted EBITDA of 7.1x. On operations, The Landing averaged 95.1% occupancy in the quarter, The Riviera averaged 25.6%, and The Pinnacle ended the quarter at 31% occupied. Management did not provide formal quarterly or full-year financial guidance on the call.
Mark Decker framed the quarter as part of a major transition from strategy development to execution, with the highest near-term priority being disposition of the legacy outpatient medical portfolio and redeployment into seniors housing. He said the company is encouraged by interest in the medical portfolio, but declined to give specifics on valuation or timing because the process is still underway. On capital allocation, he emphasized speed and discipline, saying the company is biased toward moving quickly rather than maximizing the last dollar of value, while noting that the best and fastest capital-markets outcome may be only a few hundred basis points apart from the absolute maximum value.
Bob Kiernan highlighted the quarter’s reported numbers: $0.50 NAREIT FFO per share and unit, $0.75 core FFO, 1.6% year-over-year same-store cash NOI growth in Outpatient Medical, and $5.3 million of cash G&A, which included $1.2 million of severance and transition costs. He also noted $231 million of unutilized borrowing capacity, 41% leverage under the credit agreement, and 7.1x net debt to adjusted EBITDA, adding that net debt/EBITDA will fluctuate as The Riviera and The Pinnacle lease up. In Q&A, he said the banks have been very supportive of the company’s transition and that management has told lenders it intends to run at lower leverage overall.
Analysts focused on three themes: the timing and pricing of the outpatient medical sale, the pace and quality of lease-up at The Riviera and The Pinnacle, and how lenders will view the shift from a higher-margin medical business to a lower-margin but higher-growth seniors housing platform. Management said MOB pricing has eroded by roughly 25 to 50 basis points due to treasury moves, but they still see a strong bid and are aiming for an outcome sooner rather than later. On lease-up, Bobby Zeiler said the process is nonlinear and that both assets show strong lead generation and tour growth, while concessions are being used tactically and should burn off as occupancy rises. On leverage, Kiernan said lenders have been supportive and receptive to the plan to operate at lower leverage.
The call reinforced that Chiron has a clear capital-recycling plan and a meaningful pipeline of seniors housing opportunities, with management saying it has already closed over $430 million of proprietary investments. Leadership sounded confident that the portfolio is being built around relevant, modern, private-pay communities with multiple paths to value creation, and that current lease-up assets should produce stabilized yields above 7%. Management also said the current market provides attractive off-market opportunities and that the company has more opportunities than capital it thinks makes sense to deploy.
The biggest risks are execution and timing: the outpatient medical sale process is still open-ended, and management acknowledged that pricing has weakened by 25 to 50 basis points as rates moved. The seniors housing assets are still early in lease-up, with The Riviera at 25.6% occupancy and The Pinnacle at 31%, so earnings and leverage could remain pressured while those communities stabilize. Management also flagged that occupancy and EBITDA leverage will fluctuate in the near term, and it did not provide a definitive timetable for the portfolio transition.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.1%
- Shares Outstanding
- 13.38M
- Float Shares
- 12.59M
of shares held by institutions
169 13F filers
Buy/sell ratio 1.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GMRE, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.27M | ▼ 8.58K |
| Alphaquest LLC | 32.82K | ▲ 24.65K |
| Axa Investment Managers S.A. | 29.33K | ▲ 29.33K |
| Schnieders Capital Management LLC | 18.90K | 0 |
| Cwm, LLC | 1.85K | ▲ 96 |
| First Horizon Advisors, Inc. | 1.26K | ▼ 906 |
| Allsquare Wealth Management LLC | 200 | ▼ 800 |
| Sunbelt Securities, Inc. | 5 | ▲ 3 |
Held by 57 ETFs
Biggest fund positions in GMRE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 5, 25 | Decker Mark Okey Jr | buy | 10,000 |
| Nov 14, 25 | KIERNAN ROBERT J | buy | 3,000 |
| Nov 14, 25 | Decker Mark Okey Jr | buy | 5,907 |
| Nov 14, 25 | Decker Mark Okey Jr | buy | 4,093 |
| Aug 26, 25 | Cypher Matthew | buy | 1,350 |
| Aug 15, 25 | Barber Jamie Allen | sell | 130,000 |
| Aug 15, 25 | Decker Mark Okey Jr | buy | 17,023 |
| Aug 15, 25 | Decker Mark Okey Jr | buy | 13,871 |
| Aug 7, 25 | Barber Jamie Allen | other | 130,000 |
| Aug 7, 25 | Barber Jamie Allen | other | 130,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GMRE coverage
Recent articles, reports, and earnings notes.
No research on GMRE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GMRE report →What Global Medical REIT (XRN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 8
Global Medical REIT Q2 Earnings Call Highlights
defenseworld.net · Aug 11
Global Medical REIT Q2 Earnings Call Highlights
marketbeat.com · Aug 9
JPMorgan Chase & Co. Sells 291,977 Shares of Global Medical REIT Inc. $XRN
defenseworld.net · Apr 4
Analysts Set Global Medical REIT Inc. (NYSE:GMRE) Target Price at $42.00
defenseworld.net · Mar 5
Reviewing FrontView REIT (NYSE:FVR) and Global Medical REIT (NYSE:GMRE)
defenseworld.net · Mar 5
Global Medical REIT Inc. Announces Dates for 2025 Fourth Quarter and Year-End Earnings Release and Webcast
businesswire.com · Feb 11
Global Medical REIT Inc. (NYSE:GMRE) Receives $41.50 Consensus Price Target from Brokerages
defenseworld.net · Feb 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.